Cargando…

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

INTRODUCTION: Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwarz, Adam J., Sundell, Karen L., Charil, Arnaud, Case, Michael G., Jaeger, Ralf K., Scott, David, Bracoud, Luc, Oh, Joonmi, Suhy, Joyce, Pontecorvo, Michael J., Dickerson, Bradford C., Siemers, Eric R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675941/ https://www.ncbi.nlm.nih.gov/pubmed/31388559 http://dx.doi.org/10.1016/j.trci.2019.05.007

Ejemplares similares

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia
por: Svaldi, Diana Otero, et al.
Publicado: (2022)

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
por: Abushakra, Susan, et al.
Publicado: (2020)

Peer-Led Education Expedites Deprescribing Proton Pump Inhibitors for Appropriate Veterans
por: Bowman, Mary H.
Publicado: (2020)

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
por: Aisen, Paul S., et al.
Publicado: (2011)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals
por: Dickerson, Bradford C., et al.
Publicado: (2009)

Function and clinical meaningfulness of treatments for mild Alzheimer's disease
por: Siemers, Eric, et al.
Publicado: (2016)

Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease
por: Schott, Jonathan M., et al.
Publicado: (2016)

Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
por: Maher-Edwards, Gareth, et al.
Publicado: (2015)

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease
por: Schelter, Bjoern O., et al.
Publicado: (2019)

Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging
por: Machulda, Mary M., et al.
Publicado: (2020)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
por: Chen, Yun-Fei, et al.
Publicado: (2016)

Validation of 3‐ and 5‐point severity scales to assess ARIA‐E
por: Bracoud, Luc, et al.
Publicado: (2023)

Midlife anticholinergic drug use, risk of Alzheimer's disease, and brain atrophy in community-dwelling older adults
por: Chuang, Yi-Fang, et al.
Publicado: (2017)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease
por: Sousa, Amber, et al.
Publicado: (2015)

Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
por: Wittenberg, Raphael, et al.
Publicado: (2019)

Rates of lobar atrophy in asymptomatic MAPT mutation carriers
por: Chen, Qin, et al.
Publicado: (2019)

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study
por: Landen, Jaren W., et al.
Publicado: (2017)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease
por: Wang, Chang Yi, et al.
Publicado: (2017)

Circulating metabolites are associated with brain atrophy and white matter hyperintensities
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event‐based model of disease progression
por: Firth, Nicholas C., et al.
Publicado: (2020)

Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment
por: Wang, Guoqiao, et al.
Publicado: (2015)

Comparing ARIA‐E severity scales and effects of treatment management thresholds
por: Klein, Gregory, et al.
Publicado: (2022)

Cognitive and structural cerebral changes in amnestic mild cognitive impairment due to Alzheimer's disease after multicomponent training
por: Teixeira, Camila Vieira Ligo, et al.
Publicado: (2018)

Complementary pre‐screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project
por: Boada, Mercè, et al.
Publicado: (2021)

β-Amyloid is associated with aberrant metabolic connectivity in subjects with mild cognitive impairment
por: Carbonell, Felix, et al.
Publicado: (2014)

A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia
por: Gault, Laura M., et al.
Publicado: (2015)

Managing Moral Distress in the Workplace:: Creating a Resiliency Bundle
por: Davis, Melodie, et al.
Publicado: (2020)

Prevalence of dementia and mild cognitive impairment in indigenous Bolivian forager‐horticulturalists
por: Gatz, Margaret, et al.
Publicado: (2022)

Global gray matter changes in posterior cortical atrophy: A serial imaging study
por: Lehmann, Manja, et al.
Publicado: (2012)

The personalized Alzheimer's disease cortical thickness index predicts likely pathology and clinical progression in mild cognitive impairment
por: Racine, Annie M., et al.
Publicado: (2018)

Memory concerns in the early Alzheimer's disease prodrome: Regional association with tau deposition
por: Swinford, Cecily G., et al.
Publicado: (2018)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pfhcg3k91s4e33399pbbt1mde3